EVO vs. GPCR, AGIO, AMRX, GLPG, SNDX, CPRX, SDGR, HRMY, RNA, and NAMS
Should you be buying Evotec stock or one of its competitors? The main competitors of Evotec include Structure Therapeutics (GPCR), Agios Pharmaceuticals (AGIO), Amneal Pharmaceuticals (AMRX), Galapagos (GLPG), Syndax Pharmaceuticals (SNDX), Catalyst Pharmaceuticals (CPRX), Schrödinger (SDGR), Harmony Biosciences (HRMY), Avidity Biosciences (RNA), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical preparations" industry.
Evotec (NASDAQ:EVO) and Structure Therapeutics (NASDAQ:GPCR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.
Evotec's return on equity of 0.00% beat Structure Therapeutics' return on equity.
Structure Therapeutics received 11 more outperform votes than Evotec when rated by MarketBeat users. Likewise, 77.78% of users gave Structure Therapeutics an outperform vote while only 75.00% of users gave Evotec an outperform vote.
Structure Therapeutics has lower revenue, but higher earnings than Evotec.
In the previous week, Structure Therapeutics had 8 more articles in the media than Evotec. MarketBeat recorded 8 mentions for Structure Therapeutics and 0 mentions for Evotec. Evotec's average media sentiment score of 0.55 beat Structure Therapeutics' score of 0.40 indicating that Evotec is being referred to more favorably in the media.
Evotec presently has a consensus target price of $11.00, indicating a potential upside of 108.73%. Structure Therapeutics has a consensus target price of $85.71, indicating a potential upside of 121.77%. Given Structure Therapeutics' higher probable upside, analysts plainly believe Structure Therapeutics is more favorable than Evotec.
5.8% of Evotec shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Structure Therapeutics beats Evotec on 7 of the 11 factors compared between the two stocks.
Get Evotec News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
